JBN Biotech ApS Financials, key figures and credit report
Gross profit -22.2 kDKK FY 2024 -9.9% vs 2023
EBIT -22.2 kDKK FY 2024 -9.9% vs 2023
Net debt 1 260.1 kDKK FY 2024 +7.3% vs 2023
Quick ratio 0.0 FY 2024 +0 vs 2023
Income statement (kDKK)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | -16.00 | -16.16 | -24.99 | -20.19 | -22.19 |
| EBIT | -16.00 | -16.16 | -24.99 | -20.19 | -22.19 |
| Other financial expenses | -1 184.09 | - 474.21 | - 404.42 | - 395.62 | - 397.32 |
| Income from other inv. held as non-curr. assets | 3 629.91 | 31 924.72 | |||
| Net income from associates (fin.) | 1 643.48 | 338.40 | 150.48 | 61.00 | 104.41 |
| Pre-tax profit | 4 073.30 | 31 772.75 | - 278.93 | - 354.81 | - 315.10 |
| Income taxes | 264.02 | 107.88 | 94.47 | 91.48 | 92.29 |
| Net earnings | 4 337.32 | 31 880.63 | - 184.46 | - 263.33 | - 222.81 |
Assets (kDKK)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Tangible assets total | |||||
| Holdings in group member companies | 15 666.88 | 3 005.28 | 655.76 | 716.75 | 821.16 |
| Participating interests | 27.84 | 27.84 | 27.84 | 27.84 | 27.84 |
| Investments total | 15 694.72 | 3 033.12 | 683.60 | 744.60 | 849.00 |
| Non-current loans receivable | 14 122.12 | 46 046.83 | 46 046.83 | 46 046.83 | 46 046.83 |
| Long term receivables total | 14 122.12 | 46 046.83 | 46 046.83 | 46 046.83 | 46 046.83 |
| Inventories total | |||||
| Current deferred tax assets | 412.66 | 107.88 | 106.58 | 155.47 | 230.54 |
| Short term receivables total | 412.66 | 107.88 | 106.58 | 155.47 | 230.54 |
| Cash and bank deposits | 17.85 | 23.49 | 22.46 | 21.27 | 20.08 |
| Cash and cash equivalents | 17.85 | 23.49 | 22.46 | 21.27 | 20.08 |
| Balance sheet total (assets) | 30 247.34 | 49 211.32 | 46 859.47 | 46 968.17 | 47 146.46 |
Equity and liabilities (kDKK)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Share capital | 40.00 | 40.00 | 40.00 | 40.00 | 40.00 |
| Retained earnings | - 646.05 | 3 691.27 | 35 571.90 | 35 387.44 | 35 124.11 |
| Profit of the financial year | 4 337.32 | 31 880.63 | - 184.46 | - 263.33 | - 222.81 |
| Shareholders equity total | 3 731.27 | 35 611.90 | 35 427.44 | 35 164.11 | 34 941.30 |
| Non-current liabilities total | |||||
| Current trade creditors | 12.50 | 12.50 | 12.50 | 12.50 | 12.50 |
| Current owed to group member | 13 068.88 | 3 598.83 | 1 132.64 | 1 196.05 | 1 280.16 |
| Other non-interest bearing current liabilities | 13 434.69 | 9 988.09 | 10 286.89 | 10 595.51 | 10 912.49 |
| Current liabilities total | 26 516.07 | 13 599.42 | 11 432.03 | 11 804.06 | 12 205.15 |
| Balance sheet total (liabilities) | 30 247.34 | 49 211.32 | 46 859.47 | 46 968.17 | 47 146.46 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated